[Skip to Content]
[Skip to Content Landing]
Invited Critique
May 2011May 16, 2011

Rectal Cancer: The Good, the Bad, and the Ugly: Comment on “Determining the Need for Radical Surgery in Patients with T1 Rectal Cancer ”

Author Affiliations
 

Copyright 2011 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2011

Arch Surg. 2011;146(5):544. doi:10.1001/archsurg.2011.71

The many effective therapeutic options available in the management of rectal cancer have led to greater effort toward pretreatment staging, risk stratification, and individualized treatment. More vigorous treatments carry potentially increased morbidity, longer disability, higher costs, and lasting changes in quality of life. Multimodality therapy is commonly used for “bad” (locally advanced) or “ugly” (metastatic) rectal cancers, but which ones are “good” (early) enough to be curable by local excision? This question is addressed by Dr Salinas and his colleagues.

×